Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Wyeth 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Wyeth 4Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth 4Q08

4Q Revenues: $5.3 billion (-7%)

4Q Earnings: $960 million (-5%)

FY Revenues: $22.8 billion (+2%)

FY Earnings: $4.4 billion (-2%)

Comments: Revenues dropped as Effexor sales fell 7% to $902 million in 4Q08. For the year, Effexor revenues grew 4% to $3.9 billion. Slight FY08 growth was fueled by Enbrel (+27% to $2.6 billion), Prevnar (+11% to $2.7 billion) and the nutritionals unit (+13% to $1.6 billion). Wyeth spent $115.6 million on restructuring in 4Q08, up from $63.9 million in 4Q07. In FY08, restructuring costs reached $467.0 million, pre-tax, up from $273.4 million in FY07.

According to chairman, president and chief executive officer Bernard Poussout, “Wyeth met its expectations in 2008 despite external pressures.” Wyeth will now be sold to Pfizer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters